Wegovy is the trade name of the drug semaglutide for the treatment of obesity. It is an analogue of GLP1, a hormone that is produced in the intestine after food intake (REUTERS/Jim Vondruska/Illustration/File Photo)
It may interest you: Luis Miguel’s super skinny look: what are the risks and benefits of intermittent fasting
It may interest you: What is the link between artificial sweeteners and an increased risk of diabetes and metabolic syndrome
Semaglutide is marketed in two presentations: Ozempic™ for the treatment of diabetes (in doses of 0.25, 0.5 and 1 milligrams) and Wegovy™ (semaglutide 2.4 milligrams) indicated for overweight and obesity in the elderly. to 18 years (REUTERS)
Semaglutide, in addition to controlling the glucose level, inhibits appetite, which favors weight loss, although always in combination with a proper diet and exercise (Getty Images)
According to the World Health Organization (WHO), obesity is a non-infectious pandemic, causing 2.8 million deaths annually from related diseases. (Getty)
Warn of side effects of Ozempic and other trendy weight-loss drugs
How the new drug works that allows you to lose weight, according to Dr. Alberto Cormillot
Ozempic: why a diabetes drug caught on as a weight-loss method
How is the drug that can revolutionize treatments against obesity?
